These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

447 related articles for article (PubMed ID: 16631458)

  • 21. Stepping-stones to the further advancement of androgen-deprivation therapy for prostate cancer.
    Nishiyama T; Suzuki K; Yamana K; Tonegawa E; Wako K; Takahashi K
    Expert Rev Anticancer Ther; 2006 Feb; 6(2):259-68. PubMed ID: 16445378
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hormonal therapy for prostate cancer: past, present and future.
    el-Rayes BF; Hussain MH
    Expert Rev Anticancer Ther; 2002 Feb; 2(1):37-47. PubMed ID: 12113064
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade.
    Suzuki H; Okihara K; Miyake H; Fujisawa M; Miyoshi S; Matsumoto T; Fujii M; Takihana Y; Usui T; Matsuda T; Ozono S; Kumon H; Ichikawa T; Miki T;
    J Urol; 2008 Sep; 180(3):921-7. PubMed ID: 18635218
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prostate cancer: the role of hormonal therapy.
    Salesi N; Carlini P; Ruggeri EM; Ferretti G; Bria E; Cognetti F
    J Exp Clin Cancer Res; 2005 Jun; 24(2):175-80. PubMed ID: 16110748
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intermittent androgen deprivation: clinical experience and practical applications.
    Wright JL; Higano CS; Lin DW
    Urol Clin North Am; 2006 May; 33(2):167-79, vi. PubMed ID: 16631455
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Predictors of clinical metastasis in prostate cancer patients receiving androgen deprivation therapy: results from CaPSURE.
    Abouassaly R; Paciorek A; Ryan CJ; Carroll PR; Klein EA
    Cancer; 2009 Oct; 115(19):4470-6. PubMed ID: 19637339
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Androgen annihilation as a new therapeutic paradigm in advanced prostate cancer.
    Rove KO; Crawford ED
    Curr Opin Urol; 2013 May; 23(3):208-13. PubMed ID: 23492838
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Current status and prospects of androgen depletion therapy for prostate cancer.
    Akaza H
    Best Pract Res Clin Endocrinol Metab; 2008 Apr; 22(2):293-302. PubMed ID: 18471787
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Novel agents for the management of castration-resistant prostate cancer.
    Haddad H; Garcia JA
    Curr Opin Urol; 2012 May; 22(3):175-82. PubMed ID: 22472509
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Androgen deprivation therapy for precancerous lesions of the prostate.
    Hull D; Bostwick DG
    Best Pract Res Clin Endocrinol Metab; 2008 Apr; 22(2):285-91. PubMed ID: 18471786
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Perhaps an explanation for the therapeutic escape of prostate cancer treated with antiandrogens].
    Jeanteur P
    Bull Cancer; 2000 Jul; 87(7-8):524-5. PubMed ID: 10969205
    [No Abstract]   [Full Text] [Related]  

  • 32. [Role of hormonotherapy in the treatment of metastatic prostate cancer].
    Lebret T; Méjean A
    Prog Urol; 2008 Nov; 18 Suppl 7():S332-7. PubMed ID: 19070812
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The case for secondary hormonal therapies in the chemotherapy age.
    Small EJ; Ryan CJ
    J Urol; 2006 Dec; 176(6 Pt 2):S66-71. PubMed ID: 17084172
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Second-line chemotherapy for advanced hormone-refractory prostate cancer.
    Garmey EG; Sartor O; Halabi S; Vogelzang NJ
    Clin Adv Hematol Oncol; 2008 Feb; 6(2):118-22, 127-32. PubMed ID: 18347563
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Early versus late hormonal treatment in advanced prostate cancer].
    Allepuz Losa C; Gil Martínez P; Gil Sanz MJ; Rioja Sanz LA
    Actas Urol Esp; 1999; 23(7):557-64. PubMed ID: 10488608
    [No Abstract]   [Full Text] [Related]  

  • 36. Inherited variation in the androgen pathway is associated with the efficacy of androgen-deprivation therapy in men with prostate cancer.
    Ross RW; Oh WK; Xie W; Pomerantz M; Nakabayashi M; Sartor O; Taplin ME; Regan MM; Kantoff PW; Freedman M
    J Clin Oncol; 2008 Feb; 26(6):842-7. PubMed ID: 18281655
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hormone-refractory prostate cancer: what have we learned?
    Wirth MP
    BJU Int; 2007 Jul; 100 Suppl 2():56-9. PubMed ID: 17594362
    [No Abstract]   [Full Text] [Related]  

  • 38. Targeting the androgen receptor signalling axis in castration-resistant prostate cancer (CRPC).
    Tsao CK; Galsky MD; Small AC; Yee T; Oh WK
    BJU Int; 2012 Dec; 110(11):1580-8. PubMed ID: 22985411
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunohistochemical changes in prostate cancer after androgen deprivation therapy.
    Bostwick DG
    Mol Urol; 2000; 4(3):101-6;discussion 107. PubMed ID: 11062363
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Biology of castration-recurrent prostate cancer.
    Azzouni F; Mohler J
    Urol Clin North Am; 2012 Nov; 39(4):435-52. PubMed ID: 23084522
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.